DPPG-Na RC02922
67232-81-9
Food Grade
99%
Royalchem
25kg/drum
2029-12-31
Pharmaceutical intermediates
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
1,1′-[1-[[[(2,3-Dihydroxypropoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl] dihexadecanoate sodium salt (1:1)
Other Name:Hexadecanoic acid,1,1′-[1-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl] ester,sodium salt (1:1);Hexadecanoic acid,1-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester,monosodium salt;1,1′-[1-[[[(2,3-Dihydroxypropoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl] dihexadecanoate sodium salt (1:1)
CAS No.:67232-81-9
Molecular Formula:C38H75O10P.Na
InChIKeys:InChIKey=ZDTRCZFSIBOLMV-UHFFFAOYSA-N
Categories:
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Pharmaceutical intermediates
-
Location:
Room 336, Building 7, No. 177 Xingqiao North Road, Xingqiao Street, Linping District, Hangzhou
-
Payment Terms:
TT against copy of documents,D/P,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
14
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
Less than 5
-
Year of Establishment:
2025
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product